Skip to content

News

Wei Zhou, PhD | Meet a Scientist

Wei Zhou, PhD | Meet a Scientist

Dr. Wei Zhou, of The Wistar Institute in Philadelphia, is a 2021 recipient of OCRA’s Ann & Sol Schreiber Mentored Investigator Award, mentored by Dr. Rugang Zhang. With his project, “Targeting the Mevalonate Pathway in ARID1A-Mutated Ovarian Cancer,” Dr. Zhou is investigating ARID1A mutations, in search of better therapeutic options for patients with ovarian clear … Continued

Ovarian Cancer Research Discoveries Made by OCRA Grantees in 2021

Ovarian Cancer Research Discoveries Made by OCRA Grantees in 2021

We’re pleased to report that thanks to your support, OCRA grantees made breathtaking strides toward better understanding, preventing and treating ovarian cancer this year. Read about our OCRA Grantees’ discoveries in 2020 → The results of OCRA-supported research projects have been published in some of the world’s most prestigious journals, such as: Gynecologic Oncology, Lancet Oncology, New England Journal of … Continued

The Overview: December 2021

The Overview: December 2021

This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer community — can lean in even harder to our commitment of being a voice for all those touched by the disease, and finding better treatments and a … Continued

Announcing The Edmée Firth Fund for Research in Ovarian Cancer

Announcing The Edmée Firth Fund for Research in Ovarian Cancer

Ovarian Cancer Research Alliance (OCRA) is proud to announce the establishment of a major new research partnership with Nicholas Firth and the Jean & Louis Dreyfus Foundation to be known as The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC). Established with an initial gift of $1 million, OCRA will direct the fund toward critical areas of research, … Continued

OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer

OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer

An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor type. The research, published in Science Advances and supported by multiple OCRA grants, turned up three potential drug targets for aggressive ovarian cancer, among other findings.  Scientists … Continued

Apply Today for OCRA’s 2022 Advocate Leader Program

Apply Today for OCRA’s 2022 Advocate Leader Program

The application period has now closed. Apply today to join survivors, caregivers and activists across the country to affect change for those impacted by ovarian cancer. Advocate Leaders will learn how to educate federal and state policymakers about the disease, protect funding for lifesaving research, and fight for expanded access to treatment and care. No legislative or … Continued

Liya Ding, PhD | Meet a Scientist

Liya Ding, PhD | Meet a Scientist

Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” Dr. Ding is focusing on PARP inhibitors — some of the most effective drug therapies available for ovarian cancer, but that often come with a … Continued

How to Cope With Cancer

How to Cope With Cancer

A cancer diagnosis of any type can stress both body and mind, but ovarian cancer takes a particularly high psychological toll on those living with the disease, according to recent research. However, there are different things patients can try to help them thrive during that first year. Read on for practical tips from a medical professional who … Continued

FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery

FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery

In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help doctors better locate and identify ovarian cancer lesions during surgery. The drug, which is administered via injection at the time of surgery, works by binding … Continued

Bojana Stefanovska, PhD | Meet a Scientist

Bojana Stefanovska, PhD | Meet a Scientist

Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC,” explores DNA repair as a potential treatment avenue for clear cell ovarian carcinoma (CCOC). What initially sparked your interest in science? … Continued

Ascites and Ovarian Cancer

Ascites and Ovarian Cancer

More than one-third of women with ovarian cancer develop ascites (pronounced uh٠SAI٠teez), an accumulation of fluid in the abdomen. Ascites, which also occurs in people with liver disease and occasionally with other conditions, can lead to bloating, pain, discomfort, nausea, as well as trouble moving around, eating, or breathing. While this fluid buildup often comes … Continued

A Thanksgiving Message from Audra Moran, President & CEO

A Thanksgiving Message from Audra Moran, President & CEO

Dear Friends, I hope this finds you all well, staying safe, and enjoying preparations for a lovely holiday. Whether you’re gathering with loved ones or holding them in your heart as you celebrate, I wish you warmth and joy. With the busy holiday season just around the corner, I’m grateful for this moment to reflect on … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.